126 related articles for article (PubMed ID: 2055236)
21. Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.
Barnes NM; Cheng CH; Costall B; Ge J; Naylor RJ
Br J Pharmacol; 1992 Sep; 107(1):233-9. PubMed ID: 1384906
[TBL] [Abstract][Full Text] [Related]
22. The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with high affinity in rat brain.
Waeber C; Pinkus LM; Palacios JM
Eur J Pharmacol; 1990 Jun; 181(3):283-7. PubMed ID: 2384135
[TBL] [Abstract][Full Text] [Related]
23. The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system.
Kidd E; Bouchelet de Vendegies I; Levy JC; Hamon M; Gozlan H
Eur J Pharmacol; 1992 Jan; 211(1):133-6. PubMed ID: 1618262
[TBL] [Abstract][Full Text] [Related]
24. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model.
Barnes NM; Cheng CH; Costall B; Ge J; Kelly ME; Naylor RJ
Eur J Pharmacol; 1992 Jul; 218(1):91-100. PubMed ID: 1356807
[TBL] [Abstract][Full Text] [Related]
25. The differential activities of R (+)- and S(-)-zacopride as 5-HT3 receptor antagonists.
Barnes JM; Barnes NM; Costall B; Domeney AM; Johnson DN; Kelly ME; Munson HR; Naylor RJ; Young R
Pharmacol Biochem Behav; 1990 Dec; 37(4):717-27. PubMed ID: 2128757
[TBL] [Abstract][Full Text] [Related]
26. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
[TBL] [Abstract][Full Text] [Related]
27. The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models.
Bill DJ; Coleman J; Hallett I; Middlefell VC; Rhodes KF; Fletcher A
Br J Pharmacol; 1995 Jul; 115(5):775-80. PubMed ID: 8548176
[TBL] [Abstract][Full Text] [Related]
28. Stereoselective effects of (R)- and (S)-zacopride on cognitive performance in a spatial navigation task in rats.
Fontana DJ; Daniels SE; Eglen RM; Wong EH
Neuropharmacology; 1996 Mar; 35(3):321-7. PubMed ID: 8783207
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not zacopride or GR38032F.
Mele PC; McDonough JR; McLean DB; O'Halloran KP
Eur J Pharmacol; 1992 Aug; 218(2-3):229-36. PubMed ID: 1330594
[TBL] [Abstract][Full Text] [Related]
30. Zacopride, a potent 5-HT3 antagonist.
Smith WW; Sancilio LF; Owera-Atepo JB; Naylor RJ; Lambert L
J Pharm Pharmacol; 1988 Apr; 40(4):301-2. PubMed ID: 2900319
[TBL] [Abstract][Full Text] [Related]
31. [(125I)iodo-zacopride: new ligand for the study by autoradiography of central 5-HT3 receptors].
Koscielniak T; Ponchant M; Laporte AM; Guminski Y; Verge D; Hamon M; Gozlan H
C R Acad Sci III; 1990; 311(6):231-7. PubMed ID: 2121314
[TBL] [Abstract][Full Text] [Related]
32. Agonist effects at putative central 5-HT4 receptors in rat hippocampus by R(+)- and S(-)-zacopride; no evidence for stereo-selectivity.
Boddeke HW; Kalkman HO
Neurosci Lett; 1992 Jan; 134(2):261-3. PubMed ID: 1589153
[TBL] [Abstract][Full Text] [Related]
33. Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells.
Bolaños FJ; Schechter LE; Miquel MC; Emerit MB; Rumigny JF; Hamon M; Gozlan H
Biochem Pharmacol; 1990 Oct; 40(7):1541-50. PubMed ID: 2222509
[TBL] [Abstract][Full Text] [Related]
34. Enhanced anxiolytic effect of zacopride enantiomers in diazepam-withdrawn rats.
File SE; Andrews N
Eur J Pharmacol; 1993 Jun; 237(1):127-30. PubMed ID: 8102974
[TBL] [Abstract][Full Text] [Related]
35. Comparison of potencies of 5-HT3 receptor antagonists at inhibiting aversive behavior to illumination and the von Bezold-Jarisch reflex in the mouse.
Eglen RM; Lee CH; Khabbaz M; Fontana DJ; Daniels S; Kilfoil T; Wong EH
Neuropharmacology; 1994 Feb; 33(2):227-34. PubMed ID: 8035908
[TBL] [Abstract][Full Text] [Related]
36. Association of [3H]zacopride with 5-HT3 binding sites.
Pinkus LM; Sarbin NS; Barefoot DS; Gordon JC
Eur J Pharmacol; 1989 Sep; 168(3):355-62. PubMed ID: 2583241
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of cisplatin-induced emesis in ferrets by the non-NMDA receptor antagonists NBQX and CNQX.
Fink-Jensen A; Judge ME; Hansen JB; Jacobsen P; Turski L; Olney J; Honoré T
Neurosci Lett; 1992 Mar; 137(2):173-7. PubMed ID: 1350077
[TBL] [Abstract][Full Text] [Related]
38. Physicochemical properties of serotonin 5-HT3 binding sites solubilized from membranes of NG 108-15 neuroblastoma-glioma cells.
Miquel MC; Emerit MB; Bolaños FJ; Schechter LE; Gozlan H; Hamon M
J Neurochem; 1990 Nov; 55(5):1526-36. PubMed ID: 2213008
[TBL] [Abstract][Full Text] [Related]
39. Involvement of tryptophan residue(s) in the specific binding of agonists/antagonists to 5-HT3 receptors in NG108-15 clonal cells.
Miquel MC; Emerit MB; Gozlan H; Hamon M
Biochem Pharmacol; 1991 Sep; 42(7):1453-61. PubMed ID: 1930269
[TBL] [Abstract][Full Text] [Related]
40. Identification of 5-HT3 recognition sites in the ferret area postrema.
Barnes NM; Costall B; Naylor RJ; Tattersall FD
J Pharm Pharmacol; 1988 Aug; 40(8):586-8. PubMed ID: 2907019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
